Stifel stays Buy on Oruka Therapeutics (ORKA) after Ph2a data from EVERLAST-A study

April 8, 2026 4:42 PM

Stifel analyst Alex Thompson reiterated a Buy rating and $72.00 price target on Oruka Therapeutics (NASDAQ: ORKA)The analyst commented, "2Q26 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found